Published on 18/12/2025
Regulatory Requirements for Drug Product Registration in Cameroon – global regulatory strategy for pharmaceuticals
This comprehensive tutorial aims to provide a detailed step-by-step guide for pharmaceutical professionals navigating the regulatory landscape for drug registration in Cameroon. It covers the necessary actions, documentation, and timelines, ensuring compliance with Cameroonian regulations established by the Direction de la Pharmacie et du Médicament (DPM).
Step 1: Understanding the Regulatory Framework
The first step to successfully registering a drug product in Cameroon is understanding the country’s regulatory framework. The DPM operates under the Ministry of Public Health and is responsible for overseeing the registration, quality assurance, and marketing authorization of pharmaceutical products.
Key regulations and guidelines include the following:
- Law No. 2011/022 of 14 December 2011 governing the regulation of pharmaceutical products.
- Regulatory guidelines established by the DPM, which align with global standards such as World Health Organization (WHO) recommendations.
- Good Laboratory Practices (GLP) regulations to ensure the reliability and reproducibility of laboratory studies.
Familiarizing yourself with these regulations is crucial for
Step 2: Dossier Preparation
The preparation of the registration dossier is a key phase in the drug product registration process in Cameroon. The dossier must include comprehensive data that demonstrate the drug’s safety, efficacy, and quality. The Common Technical Document (CTD) format is recommended for submissions. Key components of a typical CTD include:
行政请求
The administrative section must include:
- A cover letter addressed to the DPM.
- Application form, which can be obtained from the DPM’s website.
- Payer’s information about fees and cost, including proofs of payments.
- A summary of the drug product intended competitive positioning within the market.
技术（质量）部分
This section should contain detailed information about the drug substance and drug product, including:
- Drug substance specifications and manufacturing processes.
- Drug product formulation and specifications.
- Stability data from GLP-compliant studies.
非临床和临床研究成果
Provide comprehensive summaries of non-clinical and clinical trials, including:
- Study protocols and results, including any GLP compliance documentation.
- Risk evaluation and mitigation strategies.
- Post-marketing surveillance and pharmacovigilance plans.
Documentation must be thorough and presented clearly, as inaccuracies or missing information can lead to delays or rejection of the application. It is essential to adhere to GLP standards in the scientific studies included.
Step 3: Submission Process
Once the dossier is prepared, the next step is the submission process. The submission to the DPM involves the following steps:
预申请会议
It is advisable to hold a pre-submission meeting with the DPM. During this meeting, you can clarify submission requirements and obtain feedback on your dossier. This will help you avoid any issues later in the process.
正式提交
Submit the application dossier to the DPM. Ensure that all required documents are included, properly signed, and formatted as specified in the guidelines.
费用支付
Registration fees must be paid as per the regulatory requirements. Documentation confirming the payment should be included as part of the application.
接收确认
Upon submission, you will receive an acknowledgment from the DPM. Retain this confirmation as it serves as proof that your application packet has been received.
Step 4: Evaluation by the DPM
After submission, the DPM begins the evaluation phase. This may take several months, during which the following occurs:
初步审查
The DPM will first perform a preliminary screening to ensure all necessary documents are included and that they meet the required quality standards.
科学审查
The scientific and technical review will be conducted by experts who will evaluate the data provided regarding safety, efficacy, and quality. They may request additional information or clarification through Requests for Information (RFI).
Responding to RFIs
If RFIs are issued, respond promptly and comprehensively. Failure to do so could lead to significant delays or outright rejection of the application.
Step 5: Post-Approval Commitments
Once the product is approved, there are several post-approval commitments that must be adhered to:
市场监测
Under Cameroonian regulations, Pharmaco-vigilance plans must be implemented to monitor the drug’s safety once it is on the market. You must collect and analyze post-marketing data continuously to ensure ongoing compliance with safety standards.
跟进报告和更新
Periodic Safety Update Reports (PSURs) may be required at specified intervals, detailing any adverse events associated with the product. Keep the DPM informed about any significant changes to the manufacturing process or formulation.
合规性检查
Prepare for periodic inspections by the DPM to verify compliance with Good Manufacturing Practices (GMP) and overall quality assurance standards.
Conclusion
Acquiring drug product registration in Cameroon requires a thorough understanding of the regulatory process, meticulous preparation of the submission dossier, and adherence to post-approval commitments. With a comprehensive approach aligned with global regulatory strategies for pharmaceuticals, as outlined in this guide, pharmaceutical professionals can streamline the process and ensure compliance with DPM regulations.
For further detailed instructions and updates, refer to the DPM guidelines and consult with regulatory affairs professionals who specialize in Cameroonian pharmaceutical regulations.